0001209191-23-027051.txt : 20230503
0001209191-23-027051.hdr.sgml : 20230503
20230503170158
ACCESSION NUMBER: 0001209191-23-027051
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230501
FILED AS OF DATE: 20230503
DATE AS OF CHANGE: 20230503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCKENZIE DIANA
CENTRAL INDEX KEY: 0001754648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23885190
MAIL ADDRESS:
STREET 1: METLIFE
STREET 2: 200 PARK AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10166
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-01
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001754648
MCKENZIE DIANA
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
0
0
0
0
Common Stock
2023-05-01
4
D
0
1449
D
1435
D
Common Stock
2023-05-01
4
A
0
1168
0.00
A
2603
D
Common Stock
207
I
Held in Trust
Deferred Stock Units
2023-05-01
4
A
0
1449
A
Common Stock
1449
4566.521
D
Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units.
Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.
/s/ Christiana Stevenson, Attorney-in-Fact
2023-05-03